Dr. Bernardes will spend 4 months at the University of Pennsylvania, in Philadelphia, Pennsylvania.

His Project Proposal states: In cancer cells, the glycome is distinct from that on non-cancer cells, affecting the functionality of many overexpressed membrane oncogenes. This project will use advanced microscopy-based biophysical approaches to determine and quantify the molecular determinants involved in protein-glycan interactions between azurin(s) and brain cancer cells. This will make use of giant plasma membrane vesicles (GPMVs) originated from cell lines and primary brain tumor cells. The characterization of these interactions will foster the development nano-delivery systems like nanoparticles and exosomes engineered to surface display azurins and azurins-derived peptides to improve brain tumor treatments.